Anti-trypanosomal Activity of Bufonidae (Toad) Venom Crude Extract on Trypanosoma brucei brucei in Swiss Mice

Trypanosomiasis afflicts about 6 ~ 7 million people globally and to a large extent impedes livestock production in Africa. Naturally, trypanosomal parasites undergo genetic mutation and have developed resistance over a wide range of therapies. The utilization of animals and plants products has presented therapeutic potential for identifying novel anti-trypanosomal drugs. This study evaluated toad venom for anti-trypanosomal potency invivo in Swiss mice. Toads were collected from July to August 2019. The acute oral toxicity and biochemical characterization of the toad venom were determined. The experimental mice were administered various doses (130 mg/kg, 173 mg/kg and 217 mg/kg) of the toad venom crude extract and 0.75 mg/mL of Diamizan Plus standard drug for the treatment of trypanosomiasis, once daily for 3 days. The in-vivo anti-trypanosomal activity was evaluated by a curative test, after infecting the mice with Trypanosoma brucei brucei. The pre-patent period was 72 hours before treatment commenced. The overall results showed that trypanosomal load was highest in the control group while the group treated with Diamizan drug had the least trypanosomal load. As such, the mean trypanosomal load in relation to treatments showed a very high significant difference (P<0.05). Also, the mean trypanosomal load in Swiss mice in relation to the highest dosage of toad venom versus Diamizan drug showed a very high significant difference (P<0.05). The mean change in relation to the haematological parameters across treatments groups varied significantly (P<0.05) with the exception of Hb which showed no significant difference (P>0.05) across treatment groups. The over 50% reduction in the trypanosomal load in the 130 mg/kg group in comparison with the control group brings to bare the anti-trypanosomal potency of the toad venom. The anti-trypanosomal activity demonstrated by the toad venom has provided basis for development of new therapeutic agents from different toad species. The study recommends further studies (both in-vivo and invitro) followed by the characterization of the active compounds present in the toad venom responsible for the anti-tyrpanosomal activity observed alongside the management and conservation of these species.